BIB Short Interest

ProShares - Ultra Nasdaq Biotechnology (BIB) operates in the Financial Services sector, specifically the Asset Management industry, with a market capitalization near $80.0M, listed on NASDAQ, carrying a beta of 1.16 to the broader market. ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index. public since 2010-04-09.

Short interest is the total number of shares currently sold short and not yet covered, reported bi-monthly by FINRA. Days to cover (short interest divided by average daily volume) indicates how long it would take short sellers to close positions, with higher values signaling greater squeeze potential.

Settlement Date
2026-04-30
Short Interest
12.4K
Previous Short Interest
10.6K
Change
17.04%
Days to Cover
1.00
Avg Daily Volume
12.4K
Avg Days to Cover (24 reports)
1.58

Showing 24 bi-monthly FINRA short interest reports for ProShares - Ultra Nasdaq Biotechnology.

Learn how short interest is reported and how to read the data →

Frequently asked BIB short interest questions

What is the current BIB short interest?
As of the Apr 30, 2026 settlement, ProShares - Ultra Nasdaq Biotechnology (BIB) short interest is 12.4K shares, a +17.04% change from the prior period. FINRA publishes short interest twice monthly on the 15th and last business day of each month under Rule 4560.
What is the BIB days-to-cover ratio?
Days-to-cover is 1.00, calculated as short interest divided by average daily volume. It estimates how many trading days closing all short positions would consume given typical liquidity. Values above 5 days are commonly cited as elevated; values above 10 days are squeeze-relevant.
How does BIB short interest affect options pricing?
High short interest changes options pricing through three mechanics: borrow-rebate effects (synthetic long stock trades below frictionless put-call parity by approximately the borrow rebate when shares are hard-to-borrow), gamma-squeeze setup risk (if dealers are short gamma against retail call buying, dealer hedge flow can amplify upward moves), and elevated event-vol pricing on names with squeeze potential. See the canonical short-interest documentation for the full mechanism.